S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Federal student loan payments are starting again. Here's what you need to know
Laser breakthrough could send stock soaring 2,467% (Ad)
Stock market today: Asian shares mixed as Japan business confidence rises and US shutdown is averted
Bank of Japan survey shows manufacturers optimistic about economy
Laser breakthrough could send stock soaring 2,467% (Ad)
Facing increasing pressure from customers, some miners are switching to renewable energy
Grant program for Black women entrepreneurs blocked by federal appeals court
Laser breakthrough could send stock soaring 2,467% (Ad)
The death toll in a collapsed gold mine in Zimbabwe expected to rise to 13, vice president says
Late-night shows return after writers strike as actors resume talks that could end their standoff
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Federal student loan payments are starting again. Here's what you need to know
Laser breakthrough could send stock soaring 2,467% (Ad)
Stock market today: Asian shares mixed as Japan business confidence rises and US shutdown is averted
Bank of Japan survey shows manufacturers optimistic about economy
Laser breakthrough could send stock soaring 2,467% (Ad)
Facing increasing pressure from customers, some miners are switching to renewable energy
Grant program for Black women entrepreneurs blocked by federal appeals court
Laser breakthrough could send stock soaring 2,467% (Ad)
The death toll in a collapsed gold mine in Zimbabwe expected to rise to 13, vice president says
Late-night shows return after writers strike as actors resume talks that could end their standoff
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Federal student loan payments are starting again. Here's what you need to know
Laser breakthrough could send stock soaring 2,467% (Ad)
Stock market today: Asian shares mixed as Japan business confidence rises and US shutdown is averted
Bank of Japan survey shows manufacturers optimistic about economy
Laser breakthrough could send stock soaring 2,467% (Ad)
Facing increasing pressure from customers, some miners are switching to renewable energy
Grant program for Black women entrepreneurs blocked by federal appeals court
Laser breakthrough could send stock soaring 2,467% (Ad)
The death toll in a collapsed gold mine in Zimbabwe expected to rise to 13, vice president says
Late-night shows return after writers strike as actors resume talks that could end their standoff
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Federal student loan payments are starting again. Here's what you need to know
Laser breakthrough could send stock soaring 2,467% (Ad)
Stock market today: Asian shares mixed as Japan business confidence rises and US shutdown is averted
Bank of Japan survey shows manufacturers optimistic about economy
Laser breakthrough could send stock soaring 2,467% (Ad)
Facing increasing pressure from customers, some miners are switching to renewable energy
Grant program for Black women entrepreneurs blocked by federal appeals court
Laser breakthrough could send stock soaring 2,467% (Ad)
The death toll in a collapsed gold mine in Zimbabwe expected to rise to 13, vice president says
Late-night shows return after writers strike as actors resume talks that could end their standoff
NASDAQ:ELYM

Eliem Therapeutics (ELYM) Stock Forecast, Price & News

$2.63
+0.01 (+0.38%)
(As of 09/29/2023 08:52 PM ET)
Compare
Today's Range
$2.60
$2.73
50-Day Range
$2.59
$2.90
52-Week Range
$2.21
$4.75
Volume
22,900 shs
Average Volume
20,630 shs
Market Capitalization
$71.25 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.00

Eliem Therapeutics MarketRank™ Forecast

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
128.1% Upside
$6.00 Price Target
Short Interest
Healthy
0.21% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.42mentions of Eliem Therapeutics in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.21 out of 5 stars

Medical Sector

410th out of 970 stocks

Pharmaceutical Preparations Industry

174th out of 443 stocks


ELYM stock logo

About Eliem Therapeutics (NASDAQ:ELYM) Stock

Eliem Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in chronic pain, psychiatry, epilepsy, and other disorders of the peripheral and central nervous systems. Its lead drug candidate is ETX-123, a Kv7.2/3 potassium channel opener, which is in preclinical for the treatment of neuronal excitability disorders, such as epilepsy, pain, depression, and others; and ETX-155 for the treatment of major depressive disorder and focal onset seizures that is in Phase 2a clinical trial. The company was incorporated in 2018 and is headquartered in Redmond, Washington.

ELYM Price History

ELYM Stock News Headlines

Man Gets Into a Self-Driving Tesla… What Happens Next will Shock Everyone (Video)
“Hi, I’m Teeka Tiwari...I’m about to get in this Tesla and drive up to a facility just a few miles from here to show you what could be the secret behind Elon Musk’s new AI project… What happens next will shock you…”
Why Is Eliem Therapeutics (ELYM) Stock Up 6% Today?
Laser breakthrough could send stock soaring 2,467%
Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...
Eliem Therapeutics GAAP EPS of -$0.84
SVB Securities Keeps Their Buy Rating on Eliem Therapeutics (ELYM)
ELYM Eliem Therapeutics, Inc.
Eliem Therapeutics slashing staff amid leadership shakeup
See More Headlines
Receive ELYM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Eliem Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ELYM Company Calendar

Last Earnings
8/10/2023
Today
10/01/2023
Next Earnings (Estimated)
11/13/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ELYM
Fax
N/A
Employees
30
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$6.00
High Stock Price Forecast
$6.00
Low Stock Price Forecast
$6.00
Forecasted Upside/Downside
+128.1%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
1 Analysts

Profitability

Net Income
$-45,240,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$4.84 per share

Miscellaneous

Free Float
25,816,000
Market Cap
$71.25 million
Optionable
Not Optionable
Beta
0.47
The Best High-Yield Dividend Stocks for 2023 Cover

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

  • Dr. Andrew Levin M.D. (Age 46)
    Ph.D., Principal Financial Officer & Exec. Chairman
    Comp: $73k
  • Dr. Valerie Morisset Ph.D. (Age 53)
    Chief Scientific Officer and Exec. VP of R&D
    Comp: $617.87k
  • Ms. Emily Pimblett (Age 39)
    Principal Accounting Officer
  • Ms. Jo Palmer-Phillips Ph.D.
    Chief Devel. Officer
  • Dr. Mark Versavel M.B.A. (Age 64)
    M.D., MBA, Ph.D., Sr. VP & Chief Medical Officer













ELYM Stock - Frequently Asked Questions

Should I buy or sell Eliem Therapeutics stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Eliem Therapeutics in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street analysts is that investors should "hold" ELYM shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ELYM, but not buy additional shares or sell existing shares.
View ELYM analyst ratings
or view top-rated stocks.

What is Eliem Therapeutics' stock price forecast for 2023?

1 Wall Street research analysts have issued 1-year price objectives for Eliem Therapeutics' shares. Their ELYM share price forecasts range from $6.00 to $6.00. On average, they anticipate the company's stock price to reach $6.00 in the next year. This suggests a possible upside of 128.1% from the stock's current price.
View analysts price targets for ELYM
or view top-rated stocks among Wall Street analysts.

How have ELYM shares performed in 2023?

Eliem Therapeutics' stock was trading at $3.67 on January 1st, 2023. Since then, ELYM shares have decreased by 28.3% and is now trading at $2.63.
View the best growth stocks for 2023 here
.

Are investors shorting Eliem Therapeutics?

Eliem Therapeutics saw a drop in short interest in the month of September. As of September 15th, there was short interest totaling 37,300 shares, a drop of 14.1% from the August 31st total of 43,400 shares. Based on an average trading volume of 33,600 shares, the days-to-cover ratio is currently 1.1 days. Currently, 0.2% of the company's stock are sold short.
View Eliem Therapeutics' Short Interest
.

When is Eliem Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, November 13th 2023.
View our ELYM earnings forecast
.

How were Eliem Therapeutics' earnings last quarter?

Eliem Therapeutics, Inc. (NASDAQ:ELYM) posted its earnings results on Thursday, August, 10th. The company reported ($0.19) EPS for the quarter.

When did Eliem Therapeutics IPO?

(ELYM) raised $75 million in an initial public offering on Tuesday, August 10th 2021. The company issued 6,000,000 shares at a price of $12.50 per share. SVB Leerink, Evercore ISI, Stifel and Guggenheim Securities served as the underwriters for the IPO.

What is Eliem Therapeutics' stock symbol?

Eliem Therapeutics trades on the NASDAQ under the ticker symbol "ELYM."

How do I buy shares of Eliem Therapeutics?

Shares of ELYM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Eliem Therapeutics' stock price today?

One share of ELYM stock can currently be purchased for approximately $2.63.

How much money does Eliem Therapeutics make?

Eliem Therapeutics (NASDAQ:ELYM) has a market capitalization of $71.25 million. The company earns $-45,240,000.00 in net income (profit) each year or ($1.69) on an earnings per share basis.

How can I contact Eliem Therapeutics?

The official website for the company is www.eliemtx.com. The company can be reached via phone at 877-354-3689 or via email at investorrelations@eliemtx.com.

This page (NASDAQ:ELYM) was last updated on 10/2/2023 by MarketBeat.com Staff

My Account -